Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

Trading with an implied upside of 60.5% and an RSI of 34.6, Tempus AI, Inc. (NASDAQ:TEM) has emerged as a notable oversold ...

The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

Acupath Laboratories announced today the integration of the ArteraAI Prostate Test into its diagnostic workflows, allowing for fast and convenient delivery of treatment insights. The ArteraAI Prostate ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Pathologic concordance between prostate biopsy and radical prostatectomy improves with use of a novel robotic-assisted transperineal fusion biopsy platform. Optimization of risk stratification at ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...